GuidelineDiabetes care2018
Insulin Access and Affordability Working Group: Conclusions and Recommendations.
Guideline in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed.
- Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial.Journal of diabetes science and technology · 2023Trial
- Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (NovologBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Trial
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.Diabetes, obesity & metabolism · 2022Trial
- A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.Diabetes, obesity & metabolism · 2022Trial
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.Diabetes, obesity & metabolism · 2022Trial
- Continuous Glucose Monitoring With Low-Carbohydrate Nutritional Coaching to Improve Type 2 Diabetes Control: Randomized Quality Improvement Program.Journal of medical Internet research · 2022Trial
- State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.Diabetes care · 2026Article
- Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.AAPS PharmSciTech · 2025Review
- "Can I afford to live today?" The emotional toll of navigating the healthcare system with type 1 diabetes.Frontiers in endocrinology · 2025Article
- Continuous glucose monitoring among adults with type 2 diabetes receiving noninsulin or basal insulin therapy in primary care.Scientific reports · 2024Article
- What Primary Care Clinicians Need to Know About Once-Weekly Insulins.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024Article
- Health Outcome Changes in Individuals With Type 1 Diabetes After a State-Level Insulin Copayment Cap.JAMA network open · 2024Article
- Household food insecurity and associations with hemoglobin ADiabetes research and clinical practice · 2024Article
- The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.Endocrine reviews · 2024Review
- Developing a Diabetes Discharge Order Set for Patients With Diabetes on Insulin.Journal of diabetes science and technology · 2024Article
- The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah.Journal of managed care & specialty pharmacy · 2024Article
- The effects of patient out-of-pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance-2014-2018.Health services research · 2024Article
- [Evolution of insulin therapy: past, present, future].Problemy endokrinologii · 2024Review
- National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.BMJ global health · 2024Article
- Endocrine, genetic, and microbiome nexus of obesity and potential role of postbiotics: a narrative review.Eating and weight disorders : EWD · 2023Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.